Listen as Mayo Clinic gastroenterologist William Faubion, M.D. delivers exciting findings from a recent publication in Stem Cells Translational Medicine that details the success of a new stem cell therapy for Crohn’s fistula. The video, below, is followed up with some key points to take away from this post.
Key Points Include:
- Perianal fistulae is a painful possible complication of Crohn’s disease. According to Mayo Clinic, this complication occurs when an ulcer completely penetrates the intestinal wall, affecting about 20% of those who suffer from Crohn’s disease
- In the study, stem cells derived from patients’ fat were injected along the fistula tracts to treat the complication
- The publication provides followup on 40 patients who underwent the stem cell therapy 2 years prior, noting that 70-80% of the patients maintained full enclosure of fistula tracts over 2 years!
- This is the first treatment for Crohn’s fistulae that shows promising potential over a long-term period
Want to be better informed than your competition? Get future stem cell industry updates.
BioInformant is the only research firm that has served the stem cell sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Becton Dickinson, BioInformant is your global leader in stem cell industry data.
Click here to view our global strategic reports for the stem cell and cord blood industry.